Document Detail


Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery.
MedLine Citation:
PMID:  17073597     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Disruption of a proper regulation of cell proliferation can ultimately cause cancer. Most human B cell malignancies are driven by chromosomal translocations or other genetic alterations which directly affect the function of critical cell cycle proteins, such as cyclins and cyclin-dependent kinases. In addition, the transformation of indolent lymphomas into aggressive malignancies is often accompanied by a loss of tumor suppressors controlling important cell cycle checkpoints. A better understanding of cell cycle deregulations in human tumors has promoted the introduction of a new class of antiproliferative drugs into cancer therapies. These drugs exert their function by specifically blocking important cell cycle proteins. In the present review we discuss how alterations in the cell cycle control contribute to the malignant transformation of B cells. Furthermore, we provide an overview of novel direct and indirect cell cycle inhibitors and their impact on the treatment of patients with B cell lymphomas.
Authors:
Ingo Ringshausen; Christian Peschel; Thomas Decker
Related Documents :
10199407 - Cell cycle-dependent polar localization of an essential bacterial histidine kinase that...
2823717 - Cell-cycle dependence of dolichyl phosphate biosynthesis.
20196847 - Sulforaphane induces cell cycle arrest by protecting rb-e2f-1 complex in epithelial ova...
15576927 - Developmental control of growth and cell cycle progression in drosophila.
11163377 - Cytotoxicity of dental composite components and mercury compounds in lung cells.
12941917 - Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievir...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current drug targets     Volume:  7     ISSN:  1873-5592     ISO Abbreviation:  Curr Drug Targets     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-10-31     Completed Date:  2007-01-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1349-59     Citation Subset:  IM    
Affiliation:
Comprehensive Cancer Center, University of California, San Francisco, 2340 Sutter Street, San Francisco, CA 94115, USA. iringshausen@cc.ucsf.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / pharmacology,  therapeutic use*
Cell Cycle / drug effects*,  physiology
Cell Proliferation / drug effects*
Growth Inhibitors / pharmacology,  therapeutic use*
Humans
Lymphoma / drug therapy*,  pathology*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Growth Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Next Document:  Therapeutic targeting of apoptotic pathways in cancer.